Quick Answer
Dermata Therapeutics, Inc. reported Total Assets of $7.86 million for the year ending 2025.
- Dermata Therapeutics, Inc. showed an increase of +122.5% in Total Assets from 2024 to 2025.
- This data is from Dermata Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $1.14 million | Q3 2021: $13.69 million | Q1 2022: $9.04 million | Q2 2022: $11.03 million | Q3 2022: $8.97 million | Q1 2023: $9.30 million | Q2 2023: $8.71 million | Q3 2023: $7.32 million | Q1 2024: $5.18 million | Q2 2024: $5.24 million | Q3 2024: $6.69 million | Q1 2025: $10.01 million | Q2 2025: $6.64 million | Q3 2025: $5.07 million.
- Over the full 6 years of available data (2020 to 2025), Dermata Therapeutics, Inc.'s Total Assets has grown by 1,198.8%.
- Historical annual values: Fiscal year 2025: $7.86 million | Fiscal year 2024: $3.53 million | Fiscal year 2023: $7.98 million | Fiscal year 2022: $6.94 million | Fiscal year 2021: $11.62 million | Fiscal year 2020: $605.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: